{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:24:07Z","timestamp":1781961847145,"version":"3.54.5"},"reference-count":149,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.3109\/10428194.2013.845883","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T06:23:11Z","timestamp":1379658191000},"page":"1451-1462","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":35,"title":["Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia"],"prefix":"10.1080","volume":"55","author":[{"given":"Elias J.","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Hematology, The University of Adelaide","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Abteilung H\u00e4matologie\/Onkologie, Universit\u00e4tsklinikum Jena","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,11,12]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7146"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-380147"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90119-X"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3453159.x"},{"key":"e_1_3_2_7_1","first-page":"49","article-title":"Staging and prognosis in chronic myelogenous leukemia","volume":"25","author":"Sokal JE","year":"1988","unstructured":"Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49\u201361.","journal-title":"Semin Hematol"},{"key":"e_1_3_2_8_1","volume-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed","author":"Swerdlow SH","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: WHO Press; 2008."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21756"},{"key":"e_1_3_2_11_1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell PC","year":"1960","unstructured":"Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85\u2013109.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41246"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20922"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2815"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002094200"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.696313"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1941"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.7.2084"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.12.4189-4201.2002"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1066"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307256"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046636"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910180105"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(98)00097-6"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.7.2255-2266.2002"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.12.8.3346-3355.1992"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.10.015"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.19.11059"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603317"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-090472"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1209037"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.7.1122"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403779"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07772.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01459.x"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.668684"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/350569a0"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.11.006"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.1883"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001693542"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/79232"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20847"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb03229.x"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510423103"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206620"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404227"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"issue":"1","key":"e_1_3_2_52_1","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger M","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): Abstract 1126.","journal-title":"Blood"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0598"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V118.21.454.454","article-title":"Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP)","volume":"118","author":"Quintas-Cardama A","year":"2011","unstructured":"Quintas-Cardama A, Kantarjian HM, Luthra R, et al. Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP). Blood 2011;118(Suppl. 1): Abstract 454.","journal-title":"Blood"},{"issue":"1","key":"e_1_3_2_61_1","article-title":"Early CP CML, nilotinib 400 mg twice daily frontline: beyond 3 years, results remain excellent and stable (a GIMEMA CML Working Party Trial)","volume":"118","author":"Gugliotta G","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Breccia M, et al. Early CP CML, nilotinib 400 mg twice daily frontline: beyond 3 years, results remain excellent and stable (a GIMEMA CML Working Party Trial). Blood 2011;118(Suppl. 1): Abstract 2756.","journal-title":"Blood"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_3_2_63_1","first-page":"340","article-title":"Nilotinb 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase study","volume":"95","author":"O\u2019Dwyer EO","year":"2010","unstructured":"O\u2019Dwyer EO, Swords R, Giles F, et al. Nilotinb 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase study. Haematologica 2010;95(Suppl.):340, Abstract 0812.","journal-title":"Haematologica"},{"issue":"1","key":"e_1_3_2_64_1","article-title":"Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 phase 2 study","volume":"114","author":"O\u2019Dwyer MC","year":"2009","unstructured":"O\u2019Dwyer MC, Kent E, Parker M, et al. Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 phase 2 study. Blood 2009;114(Suppl. 1): Abstract 3294.","journal-title":"Blood"},{"issue":"1","key":"e_1_3_2_65_1","article-title":"Analysis of the GeneXpert System on the international multicentre ICORG 08-02 phase II study of nilotinib 300mg BID as frontline treatment in patients with early chronic phase chronic myeloid leukemia (ECPCML)","volume":"118","author":"O\u2019Dwyer ME","year":"2011","unstructured":"O\u2019Dwyer ME, Swords R, Giles F, et al. Analysis of the GeneXpert System on the international multicentre ICORG 08-02 phase II study of nilotinib 300mg BID as frontline treatment in patients with early chronic phase chronic myeloid leukemia (ECPCML). Blood 2011;118(Suppl. 1): Abstract 3774.","journal-title":"Blood"},{"key":"e_1_3_2_66_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6504","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up","volume":"30","author":"Hochhaus A","year":"2012","unstructured":"Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol 2012;30(Suppl.): Abstract 6504.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_3_2_72_1","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger E","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100\u2013104.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_2_73_1","article-title":"Enestnd 4-year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)","volume":"120","author":"Kantarjian HM","year":"2012","unstructured":"Kantarjian HM, Kim D-W, Issaragrisil S, et al. Enestnd 4-year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP). Blood 2012;120(Suppl. 1): Abstract 1676.","journal-title":"Blood"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24418"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348110"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166694"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184960"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2006.06.002"},{"key":"e_1_3_2_83_1","volume-title":"Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTnd 3-year data [Abstract 0584]. Presented at the 17th Congress of the European Hematology Association, 14\u201317 June 2012","author":"Hochhaus A","unstructured":"Hochhaus A, Guilhot F, Al-Ali KH, et al. Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTnd 3-year data [Abstract 0584]. Presented at the 17th Congress of the European Hematology Association, 14\u201317 June 2012, Amsterdam, The Netherlands."},{"key":"e_1_3_2_84_1","volume-title":"Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up [Abstract 0192]. Presented at the 17th Congress of the European Hematology Association, 14\u201317 June 2012","author":"Hochhaus A","unstructured":"Hochhaus A, Boqu\u00e9 C, Bradley Garelik M, et al. Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up [Abstract 0192]. Presented at the 17th Congress of the European Hematology Association, 14\u201317 June 2012, Amsterdam, The Netherlands."},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302679"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.039321"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.531"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2126"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-423418"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373902"},{"key":"e_1_3_2_92_1","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma D","year":"2010","unstructured":"Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116:2673\u20132681.","journal-title":"Cancer"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_3_2_95_1","first-page":"25","article-title":"The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era","volume":"2","author":"Oyekunle AA","year":"2012","unstructured":"Oyekunle AA, Osho PO, Aneke JC, et al. The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era. J Hematol Malign 2012;2:25\u201332.","journal-title":"J Hematol Malign"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-319038"},{"key":"e_1_3_2_97_1","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.171","article-title":"The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib","author":"Hoffmann VS","year":"2013","unstructured":"Hoffmann VS, Baccarani M, Lindoerfer D, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013 June 11. [Epub ahead of print]","journal-title":"Leukemia"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845412Y.0000000071"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.6962"},{"key":"e_1_3_2_100_1","unstructured":"Sprycel (dasatinib) [prescribing information]. Princeton NJ: Bristol-Myers Squibb Co.; 2011."},{"key":"e_1_3_2_101_1","unstructured":"Gleevec (imatinib) [prescribing information]. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2012."},{"key":"e_1_3_2_102_1","unstructured":"Tasigna (nilotinib) [prescribing information]. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2012."},{"key":"e_1_3_2_103_1","unstructured":"Bosulif (bosutinib) [prescribing information]. New York NY: Pfizer Laboratories; 2012."},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"e_1_3_2_105_1","article-title":"The biology of CML blast crisis","volume":"384","author":"Radich JP","year":"2007","unstructured":"Radich JP. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program 2007:384\u2013391.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_3_2_106_1","first-page":"2167","article-title":"Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate","volume":"8","author":"Kantarjian HM","year":"2002","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002;8:2167\u20132176.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13529"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3547"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_3_2_112_1","first-page":"1213","article-title":"Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia","volume":"88","author":"Sureda A","year":"2003","unstructured":"Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003;88:1213\u20131220.","journal-title":"Haematologica"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13068"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.110"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.627480"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.355"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_3_2_127_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6503","article-title":"PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation","volume":"30","author":"Cortes JE","year":"2012","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. J Clin Oncol 2012;30(Suppl.) Abstract:6503.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3224"},{"issue":"1","key":"e_1_3_2_129_1","article-title":"A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation","volume":"118","author":"Cortes JE","year":"2011","unstructured":"Cortes JE, Talpaz M, Kantarjian HM, et al. A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation. Blood 2011;118(Suppl. 1): Abstract 601.","journal-title":"Blood"},{"key":"e_1_3_2_130_1","unstructured":"National Cancer Institute. SEER Stat Fact Sheets: Chronic Myeloid Leukemia. Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237115"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.194"},{"key":"e_1_3_2_133_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Version 1.2013. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4945"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07832.x"},{"key":"e_1_3_2_138_1","first-page":"146","article-title":"Extramedullary disease in Ph\u2019-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance","volume":"75","author":"Inverardi D","year":"1990","unstructured":"Inverardi D, Lazzarino M, Morra E, et al. Extramedullary disease in Ph\u2019-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance. Haematologica 1990;75:146\u2013148.","journal-title":"Haematologica"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2304"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0829-4"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001625728"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0155"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03523.x"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466482"},{"key":"e_1_3_2_145_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22470"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204693"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22535"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0991-4"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.11.004"},{"key":"e_1_3_2_150_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601075973"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428194.2013.845883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:20:19Z","timestamp":1770420019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10428194.2013.845883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,12]]},"references-count":149,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.3109\/10428194.2013.845883"],"URL":"https:\/\/doi.org\/10.3109\/10428194.2013.845883","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2013-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}